β-Hydroxybutyrate inhibits inflammasome activation to attenuate Alzheimer's disease pathology.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model study with ex vivo human tissue analysis
PubMed 32958021 · doi:10.1186/s12974-020-01948-5
What was done
Researchers measured β-hydroxybutyrate (BHB) levels in red blood cells and brain parenchyma of Alzheimer's disease (AD) patients compared to non-AD controls. They also administered exogenous BHB to the 5XFAD mouse model of AD to evaluate its effects on plaque formation, microgliosis, and markers of NLRP3 inflammasome activation (Asc speck formation and caspase-1 activation).
What was found
BHB levels were lower in red blood cells and brain parenchyma of AD patients compared with non-AD controls. In the 5XFAD mouse model, exogenous BHB administration reduced plaque formation, microgliosis, Asc speck formation, and caspase-1 activation. The abstract does not report numerical values, sample sizes, or effect sizes.
Why it matters
This study links reduced ketone body levels to Alzheimer's pathology and provides preclinical evidence that elevating BHB may suppress neuroinflammation and plaque accumulation via NLRP3 inflammasome inhibition.
Limits
The abstract does not provide sample sizes, quantitative metrics, or effect sizes for either the human tissue analyses or animal experiments. Therapeutic findings were demonstrated in a transgenic mouse model rather than a clinical trial, and cognitive outcomes were not reported.
Cited by
- supports Ketogenic diets reduce brain inflammation.